KR102541238B1 - 2-아미노-퀴놀린 유도체 - Google Patents

2-아미노-퀴놀린 유도체 Download PDF

Info

Publication number
KR102541238B1
KR102541238B1 KR1020197033158A KR20197033158A KR102541238B1 KR 102541238 B1 KR102541238 B1 KR 102541238B1 KR 1020197033158 A KR1020197033158 A KR 1020197033158A KR 20197033158 A KR20197033158 A KR 20197033158A KR 102541238 B1 KR102541238 B1 KR 102541238B1
Authority
KR
South Korea
Prior art keywords
quinolin
optionally substituted
ethoxymethyl
imidazo
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197033158A
Other languages
English (en)
Korean (ko)
Other versions
KR20190141174A (ko
Inventor
리신 리
후이핑 구안
Original Assignee
버디 바이오파마슈티칼즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버디 바이오파마슈티칼즈, 인크. filed Critical 버디 바이오파마슈티칼즈, 인크.
Publication of KR20190141174A publication Critical patent/KR20190141174A/ko
Application granted granted Critical
Publication of KR102541238B1 publication Critical patent/KR102541238B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197033158A 2017-04-27 2018-04-26 2-아미노-퀴놀린 유도체 Active KR102541238B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710287322.2A CN108794467A (zh) 2017-04-27 2017-04-27 2-氨基-喹啉衍生物
CN201710287322.2 2017-04-27
PCT/CN2018/084674 WO2018196823A1 (en) 2017-04-27 2018-04-26 2-amino-quinoline derivatives

Publications (2)

Publication Number Publication Date
KR20190141174A KR20190141174A (ko) 2019-12-23
KR102541238B1 true KR102541238B1 (ko) 2023-06-08

Family

ID=63918846

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033158A Active KR102541238B1 (ko) 2017-04-27 2018-04-26 2-아미노-퀴놀린 유도체

Country Status (13)

Country Link
US (3) US11053240B2 (https=)
EP (1) EP3615539B1 (https=)
JP (1) JP7179357B2 (https=)
KR (1) KR102541238B1 (https=)
CN (3) CN108794467A (https=)
AU (1) AU2018259831B2 (https=)
BR (1) BR112019022246A2 (https=)
CA (1) CA3061187A1 (https=)
IL (1) IL270219B (https=)
MX (1) MX2019012676A (https=)
RU (1) RU2019138177A (https=)
SG (1) SG11201909325RA (https=)
WO (1) WO2018196823A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
DK3092256T3 (da) 2014-01-10 2022-06-20 Birdie Biopharmaceuticals Inc Forbindelser og sammensætninger til immunterapi
CN121243402A (zh) 2014-07-09 2026-01-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1组合
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
BR112021016960A2 (pt) * 2019-03-07 2021-11-23 BioNTech SE Processo para a preparação de uma imidazoquinolina substituída
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US11339159B2 (en) * 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
CA3170551A1 (en) 2020-03-02 2021-09-10 Yong Taik Lim Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
JP7690221B2 (ja) 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的に作用するアジュバントアンサンブル
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
US20230346924A1 (en) 2020-08-04 2023-11-02 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
CA3208424A1 (en) * 2021-02-22 2022-08-25 David M. Ferguson Immunomodulators and immunomodulator conjugates
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
MX2024000357A (es) 2021-07-07 2024-02-12 Incyte Corp Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
WO2023287896A1 (en) 2021-07-14 2023-01-19 Incyte Corporation Tricyclic compounds as inhibitors of kras
US12441742B2 (en) 2021-08-31 2025-10-14 Incyte Corporation Naphthyridine compounds as inhibitors of KRAS
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2025245175A1 (en) * 2024-05-22 2025-11-27 Ajax Therapeutics, Inc. Macrocyclic heteroaromatic inhibitors of jak2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032484A3 (en) 2003-10-03 2005-06-30 3M Innovative Properties Co Alkoxy substituted imidazoquinolines
WO2012143143A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6608201B2 (en) 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
BR0012196A (pt) 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
EP1850850A4 (en) 2000-12-08 2011-06-15 3M Innovative Properties Co COMPOSITIONS AND METHOD FOR TARGETED ADMINISTRATION OF IMMUNE RESPONSE MODIFICATORS
US20030139364A1 (en) 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
EP1455700A4 (en) 2001-11-16 2007-02-14 3M Innovative Properties Co METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
AP2004003069A0 (en) 2001-11-27 2004-06-30 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
EP1413316A1 (en) 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
CA2510375A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US20050036951A1 (en) 2003-01-09 2005-02-17 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
KR20060120069A (ko) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
CA2542099A1 (en) 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20050239735A1 (en) 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
US8012964B2 (en) 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
CA2586913A1 (en) 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
PL1830876T3 (pl) 2004-12-30 2015-09-30 Meda Ab Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi
CN101128431B (zh) 2005-02-24 2011-05-25 詹森药业有限公司 作为钾离子通道打开剂的喹啉衍生物
CN101155932A (zh) 2005-04-14 2008-04-02 默克专利有限公司 基于在肿瘤组织中增加的egfr基因拷贝数的抗egfr抗体治疗
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP1928912A4 (en) 2005-09-07 2010-02-24 Medimmune Inc EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US20080031887A1 (en) 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
BRPI0717638A2 (pt) 2006-10-27 2013-11-12 Genentech Inc Anticorpors e imunoconjugados e usos para os mesmos
MY148217A (en) 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
HRP20120895T1 (hr) 2007-05-08 2012-11-30 Astrazeneca Ab Imidazokinolini sa imuno-modulacijskim svojstvima
RU2010107199A (ru) 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
GB0715428D0 (en) * 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
EP2436376B1 (en) 2007-09-28 2014-07-09 BIND Therapeutics, Inc. Cancer cell targeting using nanoparticles
AU2008347400B2 (en) 2008-01-15 2014-12-11 Meda Ab Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
CA2713137C (en) 2008-01-25 2017-10-24 Hadasit Medical Research Services And Development Ltd. Targeting of innate immune response to tumor site
EA201001264A1 (ru) 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
EP2316032A1 (en) 2008-08-20 2011-05-04 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
EP2427485B1 (en) 2009-05-07 2016-12-07 ImmunoCellular Therapeutics, Ltd. Cd133 epitopes
WO2010132622A2 (en) 2009-05-14 2010-11-18 The Regents Of The University Of California Anticd20-cpg conjugates and methods of treating b cell malignancies
US20110077263A1 (en) 2009-09-29 2011-03-31 University Of Southern California Methods and Compositions of Toll-Like Receptor (TLR) Agonists
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2011084726A1 (en) 2009-12-21 2011-07-14 3M Innovative Properties Company BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
WO2011084725A1 (en) 2009-12-21 2011-07-14 3M Innovative Properties Company 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
KR20130108295A (ko) 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
EP3195868A3 (en) 2010-10-01 2017-08-02 VentiRx Pharmaceuticals, Inc. Therapeutic use of a tlr agonist and combination therapy
CN103476407A (zh) 2010-12-09 2013-12-25 霍夫曼-拉罗奇有限公司 用帕利他赛和曲妥珠单抗-mcc-dm1治疗her2阳性癌症
DK2663555T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
WO2012104344A1 (en) 2011-02-01 2012-08-09 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
TW201247706A (en) 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
UY34032A (es) * 2011-04-21 2012-11-30 Origenis Gmbh Nuevos inhibidores de quinasa
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
CN103748084B (zh) 2011-08-11 2016-07-06 亨斯迈先进材料美国有限责任公司 制备苯并噁嗪化合物的方法
EP2758080B1 (en) 2011-09-19 2018-03-07 The Johns Hopkins University Cancer immunotherapy
WO2013063277A1 (en) 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AU2012334825B2 (en) 2011-11-09 2017-08-24 Ascend Biopharmaceuticals Ltd Immunomodulatory conjugates
WO2013166110A1 (en) 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
TWI606063B (zh) 2012-08-23 2017-11-21 艾澤西公司 結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
EP2787005A1 (en) 2013-04-02 2014-10-08 Activartis Biotech GmbH Targeted cancer immune therapy
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
DK3092256T3 (da) 2014-01-10 2022-06-20 Birdie Biopharmaceuticals Inc Forbindelser og sammensætninger til immunterapi
WO2015200728A1 (en) 2014-06-25 2015-12-30 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
CN121243402A (zh) 2014-07-09 2026-01-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1组合
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
JP6141568B1 (ja) 2015-09-01 2017-06-07 大鵬薬品工業株式会社 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩
US10821127B2 (en) 2015-11-09 2020-11-03 Shaperon Inc. Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
AU2019335366A1 (en) 2018-09-07 2021-03-25 Birdie Biopharmaceuticals, Inc. Imidazoquinoline compounds and uses thereof
CA3125133A1 (en) 2018-12-26 2020-07-02 Birdie Biopharmaceuticals, Inc. Immune modulatory combinations and methods for treating cancers
US20220175762A1 (en) 2019-03-15 2022-06-09 Birdie Biopharmaceuticals, Inc. Immune modulatory compositions and methods for treating cancers
AU2021332350A1 (en) 2020-08-26 2023-03-16 Birdie Pharmaceuticals, Inc. Cancer treatment with TLR agonist

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032484A3 (en) 2003-10-03 2005-06-30 3M Innovative Properties Co Alkoxy substituted imidazoquinolines
KR101154101B1 (ko) 2003-10-03 2012-06-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 알콕시 치환된 이미다조퀴놀린
WO2012143143A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry, Vol.48, No.10, pp.3481-3491(2005.04.21.) 1부.*

Also Published As

Publication number Publication date
EP3615539A4 (en) 2020-08-19
SG11201909325RA (en) 2019-11-28
CN108794467A (zh) 2018-11-13
US20210261549A1 (en) 2021-08-26
CN118515666A (zh) 2024-08-20
US20200055851A1 (en) 2020-02-20
US11834448B2 (en) 2023-12-05
RU2019138177A (ru) 2021-05-27
KR20190141174A (ko) 2019-12-23
JP2020517711A (ja) 2020-06-18
MX2019012676A (es) 2020-02-05
US20210261548A1 (en) 2021-08-26
WO2018196823A1 (en) 2018-11-01
CN110637018A (zh) 2019-12-31
AU2018259831A1 (en) 2019-10-31
IL270219B (en) 2022-09-01
EP3615539B1 (en) 2023-08-09
EP3615539A1 (en) 2020-03-04
JP7179357B2 (ja) 2022-11-29
CA3061187A1 (en) 2018-11-01
CN110637018B (zh) 2025-06-06
BR112019022246A2 (pt) 2020-08-11
RU2019138177A3 (https=) 2021-05-27
IL270219A (https=) 2019-12-31
AU2018259831B2 (en) 2022-06-16
US11053240B2 (en) 2021-07-06

Similar Documents

Publication Publication Date Title
KR102541238B1 (ko) 2-아미노-퀴놀린 유도체
US10882876B2 (en) Pegylated imidazoquinolines as TLR7 and TLR8 agonists
JP6893501B2 (ja) スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン
CN114585621B (zh) 咪唑并喹啉胺衍生物、及其药物组合物和应用
EA029926B1 (ru) 1,2-дизамещенные 4-амино-имидазохинолины, содержащая их фармацевтическая композиция и их применение в качестве активаторов toll-подобных рецепторов 7 (варианты)
RU2768629C2 (ru) Замещенные имидазохинолины
EP4497752A1 (en) Pyrimido-pyridazinone compound as toll-like receptor agonist
CN114616234B (zh) 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
KR20220150356A (ko) 치료제 및 이의 접합체
CN115667274A (zh) 作为sting调节剂的杂环化合物
WO2022117090A1 (zh) 一种多环化合物及其制备方法和用途
HK40025120B (en) 2-amino-quinoline derivatives
HK40025120A (en) 2-amino-quinoline derivatives
CA3147836C (en) 2-AMINOPYRIMIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND ASSOCIATED USES
HK40068190B (zh) 咪唑并喹啉胺衍生物、及其药物组合物和应用
HK40068190A (en) Imidazoquinoline amine derivatives, pharmaceutical compositions and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191108

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210216

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221215

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230501

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230602

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230602

End annual number: 3

Start annual number: 1

PG1601 Publication of registration